News headlines about PRA Health Sciences (NASDAQ:PRAH) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PRA Health Sciences earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.6343244134315 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
Shares of NASDAQ PRAH opened at $95.22 on Monday. The stock has a market capitalization of $6.10 billion, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 1.47 and a beta of 0.49. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 1.29. PRA Health Sciences has a 52-week low of $73.05 and a 52-week high of $97.31.
PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, April 25th. The medical research company reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.84 by $0.01. The company had revenue of $701.80 million for the quarter, compared to analysts’ expectations of $694.73 million. PRA Health Sciences had a return on equity of 23.06% and a net margin of 4.07%. The business’s revenue for the quarter was up 43.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 earnings per share. analysts anticipate that PRA Health Sciences will post 3.81 EPS for the current fiscal year.
PRAH has been the topic of a number of recent research reports. Zacks Investment Research cut shares of PRA Health Sciences from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. BidaskClub raised shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 13th. Finally, ValuEngine cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Monday, May 7th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $95.67.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.